



Atty. Dkt. No. 039363-1106

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Artis, et al.
Title: PDE5A CRYSTAL
STRUCTURE AND USES
Appl. No.: 10/771,833
Filing Date: 02/03/2004
Examiner: Kim, Alexander D.
Art Unit: 1656
Confirmation Number: 9734

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below. Vanessa E. Agha (Printed Name) <i>Vanessa E. Agha</i> (Signature) November 14, 2006 (Date of Deposit)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment-IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00.


The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit

card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date November 14, 2006

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6767
Facsimile: (858) 792-6773

By 

Richard Warburg, Reg. No. 32,327
By Stephen E. Reiter, Reg. No. 31,192
Attorney for Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

(use as many sheets as necessary)

Application Number	10/771,833
Filing Date	02/03/2004
First Named Inventor	Dean R. Artis
By Unit	1656
Examiner Name	Kim, Alexander D.
Attorney Docket Number	039363-1106

Sheet 1 of 7

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	2001/0008765	07-19-2001	Shinoki et al.	
	A2	2001/0012537	08-09-2001	Anderson et al.	
	A3	2001/0014448	08-16-2001	Chappa et al.	
	A4	2001/0014449	08-16-2001	Nerenberg et al.	
	A5	2001/0016322	08-23-2001	Caren et al.	
	A6	2001/0018642	08-30-2001	Balaban et al.	
	A7	2001/0019827	09-06-2001	Dawson et al.	
	A8	2001/0039271	11-08-2001	Bunnage et al.	
	A9	2002/0009764	01-24-2002	Thompson et al.	
	A10	2002/0058606	05-16-2002	Gonzalez et al.	
	A11	2002/0065286	05-30-2002	Davies et al.	
	A12	2002/0091129	07-11-2002	Booleli	
	A13	2002/0128171	09-12-2002	Watkins et al.	
	A14	2002/0165237	11-07-2002	Fryburg et al.	
	A15	2002/0168424	11-14-2002	Shahinpoor et al.	
	A16	2002/0173502	11-21-2002	Allerton	
	A17	2004/0171062	09-02-2004	Hirth et al.	
	A18	4150949	04-24-1979	Smith	
	A19	5698401	12-16-1997	Fesik et al.	
	A20	5804390	09-08-1998	Fesik et al.	
	A21	5840485	11-24-1998	Lebl et al.	
	A22	6090912	07-18-2000	Lebl et al.	
	A23	6100254	08-08-2000	Budde et al.	
	A24	6130053	10-10-2000	Thompson et al.	
	A25	6197495	03-06-2001	Qiu et al.	
	A26	6288234	09-11-2001	Griffin	
	A27	6297021	10-02-2001	Nienaber et al.	
	A28	6465494	10-15-2002	Earle et al.	
	A29	6479493	11-12-2002	Whitehead et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/771,833
Filing Date	02/03/2004
First Named Inventor	Dean R. Artis
Art Unit	1656
Examiner Name	Kim, Alexander D.
Attorney Docket Number	039363-1106

Sheet 2 of 7

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A30	WO 99/63931	12-16-1999	The Salk Institute for Biological Studies		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A31	ASHANI and Wilson, A covalent affinity column for the purification of acetylcholinesterase. Biochem. Biophys. Acta, 276:317-322, 1972.	
	A32	BASHFORD et al., (1987) Spectrophotometry and Spectrofluorometry: A Practical Approach, pp. 91-114, IRL Press Ltd	
	A33	BOGER et al., Synthesis of a functionalized rigid bicycle[2.2.1]heptane: a useful hapten for eliciting catalytic antibodies. Journal of Organic Chemistry, 59:5078-5079, 1994.	
	A34	BOLGER, "Molecular Biology of the Cyclic AMP-Specific Cyclic Nucleotide Phosphodiesterases: A Diverse Family of Regulatory Enzymes," Cellular Signaling 6(8):851-859 (1994)	
	A35	BOS et al., The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9:165-169, 2000.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/771,833	
(use as many sheets as necessary)			Filing Date	02/03/2004	
			First Named Inventor	Dean R. Artis	
			Art Unit	1656	
			Examiner Name	Kim, Alexander D.	
			Attorney Docket Number	039363-1106	
Sheet	3	of	7		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	*2
	A36	BURGERS <i>et al.</i> , "Stereochemistry of hydrolysis of adenosine 3':5'-cyclic phosphorothioate by the cyclic phosphodiesterase from beef heart." <i>The Journal of Biological Chemistry</i> , 254 (20): 9959-9961 (1979)	
	A37	BUTCHER and SUTHERLAND, "Adenosine 3',5'-Phosphate in biological materials." <i>The Journal of Biological Chemistry</i> , 237 (4): 1244-1250 (1962)	
	A38	TAYLOR, <i>et al.</i> , "The Rapid Generation of Oligonucleotide-Directed Mutations at High Frequency Using Phosphorothioate-Modified DNA," <i>Nucleic Acids Research</i> 13:8765-8785 (1985)	
	A39	FEINBERG <i>et al.</i> , Zinc-directed inhibitors for zinc proteinases. <i>Acta Cryst.</i> , D51: 428-449, 1995.	
	A40	FELDER, E.R., "The Challenge of Preparing and Testing Combinatorial Compound Libraries in the Fast Lane, at the Front End of Drug Development," <i>Chimia</i> 48:531-541 (1994)	
	A41	FISHER, <i>et al.</i> , Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase, <i>J. Biol. Chem.</i> , 273:15559-15564 (1998).	
	A42	FITZGERALD <i>et al.</i> , Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. <i>The Journal of Biological Chemistry</i> , 265 (24): 14209-14219, 1990.	
	A43	GELLER <i>et al.</i> , HIV-1 protease and its inhibitors in Theoretical and Computational Methods in Genome Research. Edited by Sahai. New York: Plenum Press, 1997, p. 237-254.	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 7

Complete if Known

Application Number	10/771,833
Filing Date	02/03/2004
First Named Inventor	Dean R. Artis
Art Unit	1656
Examiner Name	Kim, Alexander D.
Attorney Docket Number	039363-1106

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ⁶
	A44	GILLILAND et al., Crystallization of biological macromolecules for X-ray diffraction studies. Current Opinion in Structural Biology, 6:595-603 (1996).	
	A45	GOLDBERG, et al., "O-Labeling of Guanosine Monophosphate Upon Hydrolysis of Cyclic Guanosine 3':5'-Monophosphate by Phosphodiesterase," <i>Journ. Of Biol. Chem.</i> 255:10344-10347 (1980)	
	A46	JIN, et al., "Characterization of the Structure of a Low K_m , Rolipram-sensitive cAMP Phosphodiesterase," <i>Journ. of Biol. Chem.</i> 267:18929-18939 (1992)	
	A47	KEISS et al., Beta-Galactosidase decreases the binding affinity of the insulin-like-growth-factor-II/mannose-6-phosphate receptor for the insulin-like-growth-factor II. <i>European Journal of Biochemistry</i> , 190:71-77, 1990	
	A48	KLEINBERG and Wanke, New approaches and technologies in drug design and discovery. <i>Am. J. Health-Syst Pharm.</i> , 52: 1323-1336, 1995.	
	A49	MANGANIELLO et al., Cyclic nucleotide phosphodiesterases: Structure, regulation and drug action, Beavo and Houslay, editors, New York: John Wiley & Sons, Inc., 1990, p. 61-85.	
	A50	MARYANOFF et al., Structure activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. <i>Journal of Medicinal Chemistry</i> , 41:1315-1343, 1998.	
	A51	MCPHERSON et al., The Role of X-ray crystallography in structure-based rational drug designs. Chapter 6 in <i>Chemical Structures Approaches Ration. Drug Design</i> . Edited by D.V. Weiner et al. Boca Raton: CRC Press, 1995, p. 161-179.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-3199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	10/771,833
		Filing Date	02/03/2004
		First Named Inventor	Dean R. Artis
		Art Unit	1656
		Examiner Name	Kim, Alexander D.
		Attorney Docket Number	039363-1106
Sheet	5	of	7

(use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	*6
	A52	MICHAELI, et al., "Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of cAMP Phosphodiesterase-deficient <i>Saccharomyces cerevisiae</i> ," <i>Journ. of Biol. Chem.</i> 268:12925-12932 (1993)	
	A53	PHAN et al., Extensively methylated myosin subfragment-1; Examination of local structure, interactions with nucleotides and actin, and ligand-induced conformational changes. <i>Biochemistry</i> , 33:11286-11295, 1994.	
	A54	RALL and SUTHERLAND, "Formation of a Cyclic Adenine Ribonucleotide by Tissue Particles," <i>Dept. of Pharmacology, School of Medicine</i> 1065-1076 (1957)	
	A55	ROSENBERRY et al., Purification of acetylcholinesterase by affinity chromatography and determination of active site stoichiometry. <i>The Journal of Biological Chemistry</i> , 247 (5): 1555-15565, 1972.	
	A56	SICA et al., Affinity chromatography and the purification of estrogen receptors. <i>The Journal of Biological Chemistry</i> , 248 (18): 6543-6558, 1973.	
	A57	SÖDERLING, et al., "Cloning and Characterization of a cAMP-Specific Cyclic Nucleotide Phosphodiesterase," <i>Proc. Natl. Acad. Sci. USA</i> 95:8991-8996 (1998)	
	A58	SÖDERLING, et al., "Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases," <i>Journ. Biol. Chem.</i> 273(25):15553-15558 (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/771,833	
(use as many sheets as necessary)			Filing Date	02/03/2004	
			First Named Inventor	Dean R. Artis	
			Art Unit	1656	
			Examiner Name	Kim, Alexander D.	
			Attorney Docket Number	039363-1106	
Sheet	6	of	7		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	*2
	A59	SONNENBURG, <i>et al.</i> , "Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases," <i>Journ. of Biol. Chem.</i> 270:30989-31000 (1995)	
	A60	THOMPSON, <i>et al.</i> , "Regulatory Mechanisms of Particulate Cyclic Nucleotide Phosphodiesterases," <i>Adv. in Sec. Mess. and Phosph. Res.</i> 25:165-184 (1992)	
	A61	UNDERWOOD, <i>et al.</i> , "Comparison of Phosphodiesterase III, IV and Dual III/IV Inhibitors on Bronchospasm and Pulmonary Eosinophil Influx in Guinea Pigs," <i>Journ. of Pharm. and Exp. Ther.</i> 270(1):250-259 (1994)	
	A62	WIENCEK, New strategies for protein crystallization growth. <i>Ann.Rev.Biomed.Eng.</i> , 1:505-534, (1999).	
	A63	WUTHRICH, K., "Three Dimensional Protein Structures by NMR," <i>Library of Congress</i> 176-199 (1986)	
	A64	WUTHRICH, NMR-This other method for protein and nucleic acid structure determination. <i>Acta Cryst.</i> , D51: 249-270, 1995.	
	A65	YAMAZAKI, <i>et al.</i> , "Cyclic GMP-specific, High Affinity, Noncatalytic Binding Sites on Light-activated Phosphodiesterase," <i>Journ. of Biol. Chem.</i> 255(23):11619-11624 (1980)	
	A66	YANG ET AL., Peptide analogs from E-cadherin with different calcium-binding affinities. <i>Journal of Peptide Research</i> , 55:203-215, 2000.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-796-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Dean R. Artis
				Art Unit	1656
				Examiner Name	Kim, Alexander D.
				Attorney Docket Number	039363-1106
Sheet	7	of	7		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
	A67	HAFNER et al., Biotechniques 2001 Apr;30(4):852-6, 858, 860 passim.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.